INTRODUCTION {#s1}
============

Colorectal cancer is the third most commonly diagnosed cancer in males and the second in females, with an estimated 1.4 million cases and 693,900 deaths occurring in 2012 \[[@R1]\]. Several markers like carcinoembryonic antigen, C-reactive protein, albumin and tumor necrosis factors have been reported as prognostic indicators of outcomes in patients with colorectal cancer. However, it is still difficult to predict the outcome of patients before treatment.

There is a growing body of evidence showing that elevated platelet count or thrombocytosis is associated with outcomes of colorectal cancer \[[@R2]--[@R10]\]. Early in 1998, Monreal M et al. reported a significant association between pre-operative platelet count and survival in patients with colorectal cancer. The following studies confirmed this association \[[@R2], [@R3], [@R5], [@R6]\]. However, some other studies failed to demonstrate the association between pretreatment elevated platelet count and outcomes of colorectal cancer \[[@R11]--[@R16]\]. Considering the controversial evidence, we conduct a meta-analysis to evaluate whether pretreatment elevated platelet count is a prognostic marker of colorectal cancer.

RESULTS {#s2}
=======

Study selection {#s2_1}
---------------

Electronic search identified 2604 potentially relevant references. Additional 5 references were further identified by checking the reference list. 2469 duplicates or clearly irrelevant references were excluded through reading the abstracts. 140 references were read in full and 106 references were excluded for irrelevance or lack of data on comparisons or outcomes. Four references were excluded for repeated data. Finally, 30 references fulfilled the inclusion criteria and provided data for the meta-analysis \[[@R2]--[@R31]\] (Figure [1](#F1){ref-type="fig"}).

![Flowchart of the process for the identification of relevant studies](oncotarget-07-81849-g001){#F1}

Characteristics of included studies {#s2_2}
-----------------------------------

All thirty included articles were cohort studies published from 1998 to 2016. This meta-analysis included 9123 patients. The quality score of included studies ranged from 6 to 8 stars. Hazard ratios of overall survival were available in 28 included studies and hazard ratios of disease-free survival were available in 15 included studies. Characteristics of the included studies are listed in Table [1](#T1){ref-type="table"}.

###### Characteristics of included studies

  Study                                  Number of patients   Tumor type          Disease stage   Cut-off value   Area          Study time   Age (year)   Follow-up (year)   Treatment                    Outcome                                   Quality score
  -------------------------------------- -------------------- ------------------- --------------- --------------- ------------- ------------ ------------ ------------------ ---------------------------- ----------------------------------------- ---------------
  Azab B 2014 \[[@R11]\]                 580                  colorectal cancer   I-IV            tertile         USA           2005-2011    68.6         40.5               surgery or chemotherapy      overall survival, disease-free survival   6
  Baranyai Z 2014 \[[@R2]\]              336                  colorectal cancer   I-IV            400             Hungary       2001-2011    67           36.1               surgery                      overall survival, disease-free survival   8
  Carruthers R 2012 \[[@R17]\]           115                  rectal cancer       I-III           NA              UK            2000-2005    63.8         37.1               chemoradiation and surgery   overall survival, disease-free survival   6
  Chen LL 2016 \[[@R3]\]                 503                  colorectal cancer   I-IV            300             China         2010-2013    58           33.8               surgery                      overall survival                          7
  Choi KW 2014 \[[@R12]\]                105                  colorectal cancer   I-IV            400             Korea         2005-2008    63           44                 surgery                      overall survival                          7
  Cravioto-Villanueva A 2012 \[[@R4]\]   163                  rectal cancer       I-III           350             Mexico        2000-2007    57.6         35.4               chemoradiation and surgery   overall survival                          6
  Del Prete M 2015 \[[@R18]\]            208                  colorectal cancer   IV              0.54 ULN        Italy         NA           61           NA                 chemotherapy                 overall survival                          6
  Guo T 2014 \[[@R5]\]                   310                  colorectal cancer   I-III           400             USA           2004-2013    69.9         NA                 NA                           overall survival                          6
  Jósa V 2015 \[[@R19]\]                 336                  colorectal cancer   I-IV            400             Hungary       2001-2011    66.9         NA                 surgery and chemotherapy     overall survival                          6
  Jósa V 2015 \[[@R19]\]                 166                  colorectal cancer   IV              380             Hungary       2001-2011    62           28                 surgery and chemotherapy     overall survival, disease-free survival   6
  Kandemir EG 2005 \[[@R7]\]             198                  colon cancer        I-II            400             Turkey        NA           57           47                 NA                           overall survival, disease-free survival   7
  Kaneko M 2012 \[[@R20]\]               50                   colorectal cancer   IV              400             Japan         2005-2010    61           17                 chemotherapy                 overall survival,                         7
  Kawai K 2013 \[[@R8]\]                 108                  rectal cancer       I-IV            365             Japan         2003-2012    63.3         22.5               chemoradiation and surgery   disease-free survival                     7
  Kim HJ 2015 \[[@R9]\]                  314                  rectal cancer       I-III           370             Japan         2003-2011    NA           36                 chemoradiation and surgery   overall survival, disease-free survival   7
  Kozak MM 2015 \[[@R21]\]               129                  colorectal cancer   I-III           400             USA           2005-2009    67           24.7               chemotherapy                 overall survival, disease-free survival   7
  Kronborg CS 2015 \[[@R13]\]            314                  colorectal cancer   IV              400             Denmark       2007-2011    64.5         21.3               chemotherapy                 overall survival                          7
  Lee YS 2016 \[[@R22]\]                 284                  colorectal cancer   II              450             Korea         2003-2009    65           7.67               Adjuvant therapy             overall survival, disease-free survival   8
  Lin MS 2012 \[[@R23]\]                 150                  colorectal cancer   I-IV            300             China         2006-2011    60.9         NA                 surgery or NA                overall survival                          6
  Monreal M 1998 \[[@R24]\]              180                  colorectal cancer   I-III           quertile        Spain         1994-1996    67           13                 surgery and chemotherapy     overall survival                          7
  Neal CP 2015 \[[@R25]\]                302                  colorectal cancer   IV              400             UK            2006-2010    64.8         29.7               surgery                      overall survival                          7
  Paik KY 2014 \[[@R26]\]                600                  colorectal cancer   I-IV            400             Korea         2006-2009    62.3         27.4               surgery                      overall survival, disease-free survival   8
  Qiu MZ 2010 \[[@R27]\]                 363                  colorectal cancer   I-IV            400             China         2005-2009    56           26                 NA                           overall survival                          7
  Roxburgh CS 2010 \[[@R28]\]            287                  colon cancer        I-III           400             UK            1997-2005    NA           65                 surgery and chemotherapy     overall survival                          7
  Sasaki K 2012 \[[@R29]\]               636                  colorectal cancer   I-IV            370             Japan         2002-2008    65.9         49.1               surgery and chemotherapy     overall survival, disease-free survival   8
  Shen L 2014 \[[@R14]\]                 199                  rectal cancer       II-III          300             China         2006-2011    55           31                 chemoradiation and surgery   overall survival, disease-free survival   8
  Song A 2015 \[[@R15]\]                 177                  colorectal cancer   IV              400             South Korea   2006-2013    52           3.1                chemotherapy                 overall survival                          7
  Toiyama Y 2015 \[[@R30]\]              89                   rectal cancer       I-III           300             Japan         2001-2012    65           56                 chemoradiation and surgery   overall survival, disease-free survival   8
  Wan S 2013 \[[@R31]\]                  1513                 colorectal cancer   I-IV            400             USA           1990-2010    64.9         54                 surgery and chemotherapy     overall survival, disease-free survival   8
  Wei Y 2015 \[[@R10]\]                  286                  colorectal cancer   II-III          276             China         2003-2011    62           34                 surgery and chemotherapy     disease-free survival                     7
  Zhao H 2016 \[[@R16]\]                 122                  colorectal cancer   IV              300             China         2006-2009    NA           NA                 chemotherapy                 overall survival                          7

NA, not available; ULN, upper limits of normal.

Prognostic impact of pretreatment elevated platelet count on overall survival {#s2_3}
-----------------------------------------------------------------------------

Twenty-eight studies contributed data to the analyses of overall survival \[[@R2]-[@R7], [@R9], [@R11]-[@R31]\]. Significant heterogeneity was found among studies (I^2^ = 81%, p = 0.000, Figure [2](#F2){ref-type="fig"}). Random-effect model was used. The pooled hazard ratio estimate showed that patients with pretreatment elevated platelet count had poorer overall survival compared with normal platelet count (HR = 1.837, 95% confidence interval, 1.497 to 2.255, p = 0.000, Figure [2](#F2){ref-type="fig"}).

![Forest plot showing the prognostic effect of pretreatment elevated platelet count on overall survival of colorectal cancer patients\
\*CI: Confidence interval.](oncotarget-07-81849-g002){#F2}

We performed subgroup analyses on confounding factors such as disease stage, cancer type, cut-off values, etc. The results consistently showed that patients with pretreatment elevated platelet count had poorer overall survival compared with normal platelet count in most subgroups: multivariate analysis subgroup (p = 0.000), univariate analysis subgroup (p = 0.000), preoperative subgroup (p = 0.000), metastatic disease subgroup (p = 0.027), stage I-III disease subgroup (p = 0.000), rectal cancer subgroup (p = 0.009), cut-off value ≥ 400 subgroup (p = 0.000), 300 ≤ cut-off value \< 400 subgroup (p = 0.000), cut-off value \< 300 subgroup (p = 0.043). In colon cancer subgroup, overall survival of patients with pretreatment elevated platelet count had no difference with patients with normal platelet count (p = 0.099). The detailed results of subgroup analyses were summarized in Table [2](#T2){ref-type="table"}.

###### Summarized results of meta-analysis

  Outcomes                Subgroups                                Analysis Model   Studies   Heterogeneity   Hazard Ratio   95% Confidence Interval   P-value           
  ----------------------- ---------------------------------------- ---------------- --------- --------------- -------------- ------------------------- --------- ------- -------
  Overall survival        total                                    random           28        0.000           81.006         1.837                     1.497     2.255   0.000
                          multivariable                            random           11        0.000           68.792         2.122                     1.508     2.985   0.000
                          univariable                              fixed            8         0.162           33.341         1.675                     1.331     2.108   0.000
                          preoperative                             random           20        0.000           83.380         2.015                     1.547     2.625   0.000
                          metastatic disease                       random           6         0.021           62.204         1.503                     1.047     2.157   0.027
                          stage I-III disease                      random           11        0.000           82.555         2.330                     1.461     3.715   0.000
                          rectal cancer                            random           5         0.008           70.832         2.796                     1.286     6.078   0.009
                          colon cancer                             random           2         0.088           65.731         2.594                     0.837     8.035   0.099
                          cut-off value ≥ 400 × 10^9^ / L          random           15        0.000           77.687         1.633                     1.284     2.077   0.000
                          300 ≤ cut-off value \< 400 × 10^9^ / L   random           9         0.038           51.062         2.467                     1.685     3.612   0.000
                          cut-off value \< 300 × 10^9^ / L         \-               1         \-              \-             1.496                     1.013     2.210   0.043
  Disease-free survival   total                                    random           15        0.000           82.195         1.635                     1.237     2.160   0.001
                          multivariable                            random           6         0.000           90.188         2.166                     1.234     3.802   0.007
                          univariable                              random           9         0.008           61.329         1.377                     0.992     1.909   0.056
                          preoperative                             random           14        0.000           83.175         1.751                     1.287     2.384   0.000
                          metastatic disease                       \-               1         \-              \-             0.850                     0.540     1.320   0.459
                          stage I-III disease                      random           8         0.000           78.468         1.697                     1.154     2.495   0.007
                          rectal cancer                            Fixed            5         0.194           34.037         1.588                     1.175     2.147   0.003
                          colon cancer                             \-               1         \-              \-             4.102                     1.822     9.235   0.001
                          cut-off value ≥ 400 × 10^9^ / L          random           6         0.000           81.695         1.589                     0.989     2.555   0.056
                          300 ≤ cut-off value \< 400 × 10^9^ / L   Fixed            6         0.076           49.840         2.030                     1.599     2.578   0.000
                          cut-off value \< 300 × 10^9^ / L         \-               1         \-              \-             1.853                     1.236     2.780   0.003

Prognostic impact of pretreatment elevated platelet count on disease-free survival {#s2_4}
----------------------------------------------------------------------------------

Fifteen studies contributed data to the analyses of disease-free survival. Significant heterogeneity was found among studies (I^2^ = 82%, p = 0.000, Figure [3](#F3){ref-type="fig"}). Random-effect model was used. The pooled hazard ratio estimate showed that patients with pretreatment elevated platelet count had poorer disease-free survival compared with normal platelet count (HR = 1.635, 95% confidence interval, 1.237 to 2.160, p = 0.001, Figure [3](#F3){ref-type="fig"}).

![Forest plot showing the prognostic effect of pretreatment elevated platelet count on disease-free survival of colorectal cancer patients\
\*CI: Confidence interval.](oncotarget-07-81849-g003){#F3}

The results of subgroup analyses revealed that colorectal patients with pretreatment elevated platelet count had poorer disease-free survival compared with normal platelet count in the following subgroups: multivariate analysis subgroup (p = 0.007), preoperative subgroup (p = 0.000), stage I-III disease subgroup (p = 0.007), rectal cancer subgroup (p = 0.003), colon cancer subgroup (p = 0.001), 300 ≤ cut-off value \< 400 subgroup (p = 0.000), cut-off value \< 300 subgroup (p = 0.003). In three subgroups, patients with pretreatment elevated platelet count had similar disease-free survival compared with patients with normal platelet count: univariate analysis subgroup (p = 0.056), cut-off value ≥ 400 subgroup (p = 0.056) and metastatic disease subgroup (all patients received R0 resection of primary and metastasis tumors) (p = 1.320). The detailed results of subgroup analyses were summarized in Table [2](#T2){ref-type="table"}.

Publication bias {#s2_5}
----------------

Visual inspection of the funnel plot for overall survival and disease-free survival outcomes did not show the typically asymmetry associated with publication bias (Figure [4](#F4){ref-type="fig"}, Figure [5](#F5){ref-type="fig"}). Evidence of publication bias was also not seen with the Begg\'s tests of overall survival (p = 0.441) and disease-free survival (p = 1.000).

![Funnel plot showing the publication bias of overall survival](oncotarget-07-81849-g004){#F4}

![Funnel plot showing the publication bias of disease-free survival](oncotarget-07-81849-g005){#F5}

Sensitivity analyses {#s2_6}
--------------------

The result of Sensitivity analyses demonstrated that no individual study had excessive influence on the stability of the pooled effect of comparisons for overall survival (Figure [6](#F6){ref-type="fig"}) and disease-free survival (Figure [7](#F7){ref-type="fig"}). The result of this meta-analysis is robust.

![Forest plot showing the sensitivity analyses of overall survival\
\*CI: Confidence interval](oncotarget-07-81849-g006){#F6}

![Forest plot showing the sensitivity analyses of disease-free survival\
\*CI: Confidence interval](oncotarget-07-81849-g007){#F7}

DISCUSSION {#s3}
==========

Elevated platelet count or thrombocytosis is observed in patients with various kinds of cancer and reported inversely correlated with survival \[[@R24], [@R32]--[@R36]\]. It was reported that nearly 10% to 30% of patients with colorectal cancer had elevated platelet count before treatment and worse survival than those with normal platelet count \[[@R2]-[@R5], [@R7], [@R9], [@R21]\]. In our study, the results demonstrated that elevated platelet count was associated with shorter overall survival and disease-free survival in patients with colorectal cancer. Subgroup analyses demonstrated that the impact of elevated platelet count are consistent in different disease stages, tumor locations and analysis models. The result of our study is robust. This evidence indicated that platelet could be a simple and robust prognostic marker to identify high risk patients. Those patients should be taken into account to receive adjuvant therapy or maybe anti-platelet medications. There have been accumulating evidence that postdiagnosis aspirin therapy can improve overall survival of patients with colorectal cancer in recent years \[[@R37]\].

It is noteworthy that the cut-off values applied in included studies were not unified. Most studies used 400 × 10^9^/L as cut-off value and some studies used 300 × 10^9^/L. The optimal cut-off value, however, was not validated in previous studies. The subgroup analyses reached consistent results among different cut-off value subgroup. The cut-off value ≥ 400 × 10^9^ / L and between 300 and 400 can both distinguished patients well by overall survival and disease-free survival. Only in cut-off value ≥ 400 × 10^9^ / L subgroup, platelet count failed to predict the disease-free survival of patients (p = 0.056, Table [2](#T2){ref-type="table"}). Regarding this, it may be reasonable to suggest that the cut-off value between 300 and 400 × 10^9^ / L be applied in further investigation.

The mechanisms of tumor-related elevated platelet count or thrombocytosis remain undetermined. One of the potential hypotheses is that thrombocytosis is usually associated with inflammatory cytokines induced by interactions between tumor and host. Among these cytokines, IL-6, having multiple functions in many physiological conditions, plays a very important role in the formation of thrombocytosis \[[@R38]\]. By stimulating differentiation of megakaryocytes to platelets in the bone marrow, IL-6 induced thrombocytosis in various malignancies \[[@R39]\]. For another explanation of cancer-associated thrombocytosis, tumor can stimulate activation of platelet. As reported in several studies that cancer cells can secrete vascular endothelial growth factor to stimulates megakaryocyte differentiation \[[@R40]\]. For the prognostic association between elevated platelet count and patients\' outcomes, there is a most widely accepted hypothesis that activated platelets contribute to the tumor growth, angiogenesis and metastasis by releasing various cytokines with inflammatory, proliferative and angiogenic activity \[[@R41]--[@R43]\]. With regard to tumor metastasis, platelets can cover and protect circulating tumor cells from the host\'s immune system. With these underlying mechanisms, platelets may be a direct or indirect target for cancer therapy.

There are some limitations of this study. First, our analysis is based on low-level evidence retrospective studies, in most of which some important confounders were not well adjusted, such as tumor stage, therapeutic strategy or ratio of colon and rectal cancer. The result of subgroup analysis, however, demonstrated that the negative prognostic significance of thrombocytosis on overall survival and disease-free survival was consistent between groups. Subgroup analysis according to therapeutic strategies was not performed because of insufficient data. Second, the sample size of some included studies were very small. The results of subgroup analyses still confirm the prognostic significance of thrombocytosis. Third, although the platelet count is easy to measure, its utility as a clinical prognostic marker could be affected by some other conditions, such as thrombosis, coronary disease, splenic disease, myeloproliferative disease, blood coagulation disorders, iron deficiency anemia and drugs. Actually, some heterogeneity was unexplainable.

In conclusion, our study demonstrated that the pretreatment elevated platelet count was an independent prognostic factor of overall survival and disease-free survival in colorectal cancer patients. It may make sense that patients with elevated platelet count should receive intensive treatment or anti-platelet therapy. And large-scale prospective studies and a validation study are warranted to confirm its prognostic significance and determine the optimal platelet cut-off value.

MATERIALS AND METHODS {#s4}
=====================

Eligibility criteria {#s4_1}
--------------------

This meta-analysis was performed according to the statement of Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) \[[@R44]\]. Cohort studies, being published from inception to July 9, 2016, which reported comparisons of overall survival or disease-free survival between colorectal cancer patients with pretreatment elevated platelet count and those patients with pretreatment normal platelet count. The study participants had been pathologically diagnosed colorectal cancer patients.

Search strategy {#s4_2}
---------------

An electronic search in PubMed, EMBASE and the Cochrane Library were conducted from inception to July 9, 2016. The following key words in combination as medical subject heading terms and text words were used: "colorectal cancer" and "platelet" or "thrombocytosis". Potentially relevant articles were identified by reading titles and abstracts. The full texts of the relevant articles were read to determine whether they met the inclusion criteria. The references were also searched to identify relevant studies.

Quality assessment {#s4_3}
------------------

For cohort studies, the 9-star Newcastle-Ottawa Scale was used to assess the risk of bias \[[@R45]\]. This scale is an 8-item instrument that allows for assessment of patient population and selection, study comparability, follow-up, and outcome. Interpretation of the scale is performed by awarding points for high-quality elements. Studies with 5 or more stars were defined as high-quality studies and were included.

Statistical analyses {#s4_4}
--------------------

Data was extracted using a unified form and study information including author name, study year, study area, sample size, hazard ratio of overall survival or disease-free survival were collected. If the hazard ratio was not reported in the original article, we would calculate hazard ratio from reported data according to the methods described by Tierney et al \[[@R46]\]. Statistical heterogeneity among studies was examined using the Cochrane Q test by calculating the I^2^ value \[[@R47]\]. The I^2^ value greater than 50% or p value less than 0.05 were considered to represent significant heterogeneity. The pooled hazard ratio and the 95% confidence interval were calculated using the Z test. The pooled hazard ratio and the 95% confidence interval were calculated using the Mantel-Haenszel formula (fixed-effect model) when heterogeneity was not detected (p \> 0.05), or using the DerSimonian-Laird formula (random-effect model) when heterogeneity was significant (p \< 0.05) \[[@R48]\]. Publication bias was evaluated using the funnel plot and the Begg\'s test \[[@R49]\]. Influence analyses were conducted to access how robust the pooled estimators were by removing individual studies. An individual study was suspected of excessive influence if the point estimate of its omitted analysis was outside the 95% confidence interval of the combined analysis. Statistical analyses were performed with Comprehensive Meta Analysis professional version 2.2 (Biostat Inc, Englewood NJ, [www.meta-analysis.com](http://www.meta-analysis.com/)).
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